Your session is about to expire
← Back to Search
Infliximab + IVIG for Pneumonitis
Study Summary
This trial is testing a new immunotherapy treatment for pneumonitis that has not responded to steroids. The treatment consists of two parts: a monoclonal antibody called infliximab, and intravenous immunoglobulin therapy. It is not yet known whether this new treatment is more effective than existing treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My recent lung test showed no infection.I tested negative for tuberculosis within the last 14 days.My severe lung inflammation hasn't improved despite recent high-dose steroid treatment.You need to have a chest CT scan without dye within 14 days before starting the study. You should not have any health issues that would make it unsafe for you to have a CT scan.I have received anti-PD-1/PD-L1 therapy before.I am not currently undergoing radiation therapy to the chest.I've had recent tests showing no infection in my blood, urine, or lungs.I am using or willing to use effective birth control or abstain from sex for at least 56 days.I am not pregnant or breastfeeding.My lung inflammation hasn't improved with steroid treatment.I was treated with an anti-PD-1/PD-L1 agent before getting pneumonitis.I am willing to have a test that measures the oxygen and carbon dioxide levels in my blood.I have a solid tumor or blood cancer.I have had previous treatments for my condition.I can care for myself but may not be able to do heavy physical work.I do not have heart problems causing my lung issues.I do not have lung conditions needing steroids.I am not on anti-PD-1/-PD-L1 therapy combined with specific cancer drugs.I haven't needed steroids for lung inflammation from radiation in the last 3 months.I don't have severe allergies, certain infections, or conditions that IVIG or infliximab would worsen.My lung inflammation hasn't improved in over 72 hours.
- Group 1: Arm A (infliximab)
- Group 2: Arm B (intravenous immunoglobulin therapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what ailments is Intravenous Immunoglobulin Therapy commonly prescribed?
"Intravenous Immunoglobulin Therapy is an oft-used treatment for scalp structure, and also has applications with regards to thyroiditis, psoriasis, and ulcerative colitis."
Is recruitment for this clinical trial still ongoing?
"Per the data on clinicaltrials.gov, this research is presently accepting participants. The investigation was originally published on July 1st 2021 and most recently amended on August 10th 2022."
To what extent has Intravenous Immunoglobulin Therapy been studied in past clinical trials?
"Intravenous Immunoglobulin Therapy began its tenure in the scientific world at Providence Cancer Center, and since then 1404 studies have been completed. Currently there are 481 trials underway, mostly located in Muskegon, Maryland."
In what locations is this trial being conducted?
"This medical study is being operated at 18 different locations, some of which include Mercy Health Mercy Campus in Muskegon, Marie Yeager Cancer Center in Saint Joseph and Cancer and Hematology Centers of Western Michigan - Norton Shores. The other 15 clinical trial sites can be found on the official website."
Could you expound upon the potential risks involved with Intravenous Immunoglobulin Therapy?
"The safety rating of Intravenous Immunoglobulin Therapy was estimated to be 2, as there is evidence that it is safe but no clinical studies yet supporting its efficacy."
To what extent is the current experiment being populated by participants?
"Correct. Clinicaltrials.gov shows that this medical study, first posted on the 7th of January 2021, is still currently recruiting patients. An estimated 36 people must be recruited from 18 separate sites."
Share this study with friends
Copy Link
Messenger